Correctly folded etanercept in high purity and excellent yield

• US 11,001,627 B2
• Filed: 09/29/2017
• Issued: 05/11/2021
• Est. Priority Date: 09/11/2012
• Status: Active Grant

• Current Assignee: Coherus BioSciences Inc.
• Original Assignee: Coherus BioSciences Inc.
• Inventors: Arakawa, Tsutomu, Farrar, Douglas
• Primary Examiner(s): D'Ambrosio, Thea
• Application Number:
  US15/720,291
• Publication Number:
  US 20180037642A1
• Time in Patent Office: 1,320 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 1/165 mixed-mode chromatography
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.

Claims

1. An etanercept-containing protein mixture comprising correctly folded etanercept in an amount constituting greater than 95 wt % and less than 5 wt % incorrectly folded etanercept of the protein mixture, and

wherein said etanercept-containing protein mixture contains 0 to 25 mM NaCl and does not contain arginine or cysteine, and

wherein said incorrectly folded etanercept is an etanercept protein that has a conformation different from that of the correctly folded etanercept and said different conformation renders said incorrectly folded etanercept protein lacking in biological activity as a TNF inhibitor and said incorrectly folded etanercept is not an aggregate,

wherein said protein mixture is obtained by using a mixed-mode chromatography method involving binding correctly folded etanercept and incorrectly folded etanercept to a mixed-mode chromatography resin having both ion exchange and hydrophobic moieties and contacting the mixed-mode chromatography resin to elute with a salt solution at a pH between 4.5 and 8.5.

2. The etanercept-containing protein mixture of claim 1, wherein hydrophobic interaction chromatography (HIC) is not used to separate said incorrectly folded etanercept from said correctly folded etanercept.

3. A pharmaceutically acceptable formulation comprising the etanercept-containing protein mixture of claim 1.

4. The pharmaceutically acceptable formulation of claim 3, wherein the correctly folded etanercept constitutes about 25 to about 75 mg/ml of the protein mixture.

5. The pharmaceutically acceptable formulation of claim 4 further comprising a buffer, a tonicity modifier, and a surfactant;

wherein the formulation has a pH between about 5.8 and 8.4, and wherein said pharmaceutically acceptable formulation contains about 25 mM NaCl.

6. The pharmaceutically acceptable formulation of claim 5, wherein the formulation contains at least 98 wt % correctly folded etanercept.

7. The pharmaceutically acceptable formulation of claim 3 further comprising a buffer.

8. The pharmaceutically acceptable formulation of claim 3 further comprising a tonicity modifier, wherein said pharmaceutically acceptable formulation contains about 25 mM NaCl.

9. The pharmaceutically acceptable formulation of claim 3 further comprising a sugar, polyol, or both a sugar and polyol.

10. The pharmaceutically acceptable formulation of claim 3 further comprising an amino acid that is not arginine or cysteine.

11. The pharmaceutically acceptable formulation of claim 3 further comprising a surfactant.

12. The pharmaceutically acceptable formulation of claim 3, wherein the formulation contains at least 98 wt % correctly folded etanercept.

13. The pharmaceutically acceptable formulation of claim 3, wherein the formulation has a pH between about 5.8 and about 8.4.

14. The pharmaceutically acceptable formulation of claim 3, wherein the formulation has an osmolality from about 180 to about 420 mOsM.

15. The pharmaceutically acceptable formulation of claim 3, further comprising an aqueous buffer selected from the group consisting of phosphate, histidine, citrate, maleate, tartrate, acetate, tris-(hydroxymethyl)-aminomethane (tris), and bicarbonate.

16. The pharmaceutically acceptable formulation of claim 15, comprising about 25 to about 75 mg/ml correctly folded etanercept.

17. The pharmaceutically acceptable formulation of claim 16 further comprising a buffer, a tonicity modifier, and a surfactant;

wherein the formulation has a pH between about 5.8 and 8.4, and wherein said pharmaceutically acceptable formulation contains about 25 mM NaCl.

18. The pharmaceutically acceptable formulation of claim 15 further comprising 0.1 to 2 wt % of a combination of a sugar and an amino acid, wherein the amino acid is not arginine and is not cysteine.

19. The pharmaceutically acceptable formulation of claim 15, wherein the amount of said incorrectly folded etanercept in the protein mixture is less than 3 wt % of said mixture.

20. The pharmaceutically acceptable formulation of claim 15, comprising about 10 mM to about 200 mM of sodium citrate.

21. The pharmaceutically acceptable formulation of claim 15, wherein the pharmaceutically acceptable formulation has a pH of 6.2 to 7.4.

22. The pharmaceutically acceptable formulation of claim 15 further comprising a surfactant.

23. The pharmaceutically acceptable formulation of claim 15, wherein the formulation has a pH between about 5.8 and about 8.4.

24. The pharmaceutically acceptable formulation of claim 15, wherein the formulation has an osmolality from about 180 to about 420 mOsM.

25. A method for treating a subject suffering from a TNF mediated disease, comprising administering to such subject the pharmaceutically acceptable formulation of claim 3.

26. The method of claim 25, wherein the TNF mediated disease is rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, or ankylosing spondylitis.

27. A method for treating a subject suffering from a TNF mediated disease, comprising administering to such subject the pharmaceutically acceptable formulation of claim 15.

28. The method of claim 27, wherein the TNF mediated disease is rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, or ankylosing spondylitis.